Fig. 1



50 mg-FH-No
50 mg-FH-Yes
PBO-FH-No
PBO-FH-Yes
50 mg-combined
PBO-combined
% Change from Baseline
Days
45
35
25
15
5
-5
-15
-25
-35
-45
-55
-65
-75
-85
-10
0
10
20
30
40
50
60
70
80
90

Fig. 2



100 mg-FH-No
100 mg-FH-Yes
PBO-FH-No
PBO-FH-Yes
100 mg-combined
PBO-combined
% Change from Baseline
Days
45
35
25
15
5
-5
-15
-25
-35
-45
-55
-65
-75
-85
-10
0
10
20
30
40
50
60
70
80
90

Fig. 3



150 mg-FH-No
150 mg-FH-Yes
PBO-FH-No
PBO-FH-Yes
150 mg-combined
PBO-combined
% Change from Baseline
Days
45
35
25
15
5
-5
-15
-25
-35
-45
-55
-65
-75
-85
-10
0
10
20
30
40
50
60
70
80
90

Fig. 4




* NCEP-ATPIII TLC or equivalent diet
Screening visit
(Open run-in: atorvastatin)
Screening period 7 weeks
R
N=30
316P + atorvastatin 80 mg
N=30
316P placebo + atorvastatin 80 mg
N=30
316P + atorvastatin 10 mg (maintenance dose)
Treatment period (8 weeks)
FU period (8 weeks)
Diet*
W -7 D -49
W -1 D -7
W 0 D 1
W 2 D 15
W 4 D 29
W 6 D 43
W 8 D 57
W 12 D 85
W 16 D 113

Fig. 5


FU period (8 weeks)
Treatment period (8 weeks)
316P + atorvastatin 80 mg
316P placebo + atorvastatin 80 mg
316P + atorvastatin 10 mg (maintenance dose)
N=30
N=30
N=30
R
Screening period 1 week
Screening visit
Diet*
W -1 D -7
W 0 D 1
W 2 D 15
W 4 D 29
W 6 D 43
W 8 D 57
W 12 D 85
W 16 D 113
* NCEP-ATPIII TLC or equivalent diet



Placebo
50mgE2W
200mgE4W
300mgE4W
100mgE2W
150mgE2W
LDL-C Mean (+/-SE) % change from baseline
10
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
BASELINE
WEEK 2
WEEK 4
WEEK 6
WEEK 8
WEEK 10
WEEK 12
LOCF
Time point
Placebo (N=20)
316P 200 mg E4W (N=20)
316P 300 mg E4W (N=21)
316P 50 mg E2W (N=19)
316P 100 mg E2W (N=20)
316P 150 mg E2W (N=18)

Fig.6